CTOs on the Move

Pediatric Associates

www.pediatricassociates.com

 
Pediatric Associates has been caring for infants, children and adolescents since 1955. Pediatric Associates opened its first office in Hollywood, FL. Since then, our physicians have cared for four generations of families with our first patients now bringing their children, grandchildren and great-grandchildren to our practice. From South Florida to Tampa and Jacksonville, across the state of Florida and now across the country, Pediatric Associates has more than 200 locations nationwide.
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Hakan Kardes
Chief Operating Officer Profile
Brent Wheeler
Vice President, Head of Data & Analytics Profile

Similar Companies

Angstrom Pharmaceuticals

Angstrom Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Azur Pharma

Azur Pharma is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boc Sciences

Boc Sciences is a Shirley, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intersciences Inc

Intersciences Inc is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.